Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the treatment of metastatic colorectal cancer that progressed or could not be tolerated after previous fluorouracil, oxaliplatin, and irinotecan based therapy

Trial Details

NCT ID
NCT06118762
Phase
PHASE4
Sponsor
The First Affiliated Hospital of Nanchang University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Fruquintinib
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306

Key Eligibility Criteria

  • Have fully understood the study and voluntarily signed the informed consent;
  • Age ≥18 years old, gender unlimited;
  • Advanced metastatic colorectal adenocarcinoma confirmed by histopathology;
  • The patient progressed or was intolerant after receiving at least previous standard therapy containing fluorouracil, oxaliplatin, and irinotecan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →